MX2009006080A - Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades. - Google Patents

Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.

Info

Publication number
MX2009006080A
MX2009006080A MX2009006080A MX2009006080A MX2009006080A MX 2009006080 A MX2009006080 A MX 2009006080A MX 2009006080 A MX2009006080 A MX 2009006080A MX 2009006080 A MX2009006080 A MX 2009006080A MX 2009006080 A MX2009006080 A MX 2009006080A
Authority
MX
Mexico
Prior art keywords
prodrugs
gaba analogs
disease
treating diseases
fibromyalgia
Prior art date
Application number
MX2009006080A
Other languages
English (en)
Inventor
Kenneth C Cundy
Ronald W Barret
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of MX2009006080A publication Critical patent/MX2009006080A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos para utilizar análogos de GABA y composiciones farmacéuticas de los mismos para el tratamiento de migraña, fibromialgia, esclerosis lateral amiotrófica, síndrome de intestino irritable, fobia social, enfermedad de Parkinson, asma, tos o enfermedad pulmonar obstructiva crónica, y composiciones farmacéuticas de profármacos de análogos de GABA útiles para tratar migraña, fibromialgia, esclerosis lateral amiotrófica, síndrome de intestino irritable, fobia social, enfermedad de Parkinson, asma, tos, o enfermedad pulmonar obstructiva crónica.
MX2009006080A 2006-12-08 2007-12-06 Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades. MX2009006080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87356106P 2006-12-08 2006-12-08
PCT/US2007/024944 WO2008073257A1 (en) 2006-12-08 2007-12-06 Use of prodrugs of gaba analogs for treating diseases

Publications (1)

Publication Number Publication Date
MX2009006080A true MX2009006080A (es) 2009-07-14

Family

ID=39186816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006080A MX2009006080A (es) 2006-12-08 2007-12-06 Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.

Country Status (13)

Country Link
US (2) US20080161393A1 (es)
EP (1) EP2101752A1 (es)
JP (1) JP2010512314A (es)
CN (1) CN101652133A (es)
AR (1) AR064212A1 (es)
AU (1) AU2007332904A1 (es)
BR (1) BRPI0720252A2 (es)
CA (1) CA2672044A1 (es)
EA (1) EA200970487A1 (es)
MX (1) MX2009006080A (es)
PE (1) PE20081389A1 (es)
TW (1) TW200845959A (es)
WO (1) WO2008073257A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
SG147437A1 (en) * 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
MX2007005306A (es) 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI369982B (en) * 2007-01-11 2012-08-11 Xenoport Inc Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
KR20110117216A (ko) * 2009-03-03 2011-10-26 제노포트 인코포레이티드 Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태
CA2823974A1 (en) * 2010-01-08 2011-07-14 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of migraine headaches
WO2012083128A2 (en) * 2010-12-16 2012-06-21 The Mclean Hospital Corporation Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
WO2014047413A1 (en) * 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
EP2961730A2 (en) 2013-02-26 2016-01-06 XenoPort, Inc. Method of making 1-(acyloxy)-alkyl carbamate compounds
WO2016187595A2 (en) * 2015-05-20 2016-11-24 Lupin Atlantis Holdings Sa Oral pharmaceutical composition of methylergonovine
CN107271599A (zh) * 2016-04-08 2017-10-20 上海市刑事科学技术研究院 一种人唾液中地西泮及其代谢物的在线spe lc-ms/ms分析方法
EP3704271B1 (en) 2017-11-02 2026-01-28 California Institute of Technology Neurokinin antagonists and uses thereof
CA3099775A1 (en) * 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin
US11776800B2 (en) * 2019-06-20 2023-10-03 Hitachi High-Tech Corporation Substance analyzer and substance analysis method
RU2709527C1 (ru) * 2019-07-29 2019-12-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Применение пептида Met-Glu-His-Phe-Pro-Gly-Pro (семакса) для коррекции дисбиоза при хроническом иммобилизационном стрессе
US12147601B1 (en) 2022-04-28 2024-11-19 Snap Inc. Removing eye blinks from EMG speech signals
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia
WO2025101272A1 (en) * 2023-11-11 2025-05-15 Css Pharma L.L.C. Pharmaceutical composition for the acute treatment of migraine and other forms of headache

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
DE3475065D1 (en) * 1983-06-23 1988-12-15 Merck & Co Inc (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5151448A (en) * 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5684018A (en) * 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
UA49011C2 (uk) * 1996-03-14 2002-09-16 Варнер-Ламберт Компані Похідні циклічної амінокислоти, фармацевтична композиція та спосіб лікування
US6020370A (en) * 1996-03-14 2000-02-01 Warner-Lambert Company Bridged cyclic amino acids as pharmaceutical agents
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6375987B1 (en) * 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
US6329429B1 (en) * 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6680343B1 (en) * 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
JP2002520277A (ja) * 1998-07-09 2002-07-09 ワーナー−ランバート・カンパニー 不眠症を治療する方法
US6490454B1 (en) * 1998-08-07 2002-12-03 Telefonaktiebolaget Lm Ericsson (Publ) Downlink observed time difference measurements
DK1169060T3 (da) * 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
GB2362646A (en) * 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
AU2002211863A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
AU2002230398A1 (en) * 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
US20040002543A1 (en) * 2001-02-16 2004-01-01 Leslie Magnus Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2449729C (en) * 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
RU2004117211A (ru) * 2001-11-08 2005-03-27 Сепракор, Инк. (Us) Способы лечения депресии и других рассстройств цнс с использованием энантиомерно обогащшенных десметил-и дидесметилметаболитов циталопрама
CN1625393A (zh) * 2002-01-31 2005-06-08 沃纳-兰伯特公司 治疗耳鸣的α2δ配体
AU2003222033A1 (en) * 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
US7060727B2 (en) * 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP1572187A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders
KR100709159B1 (ko) * 2002-12-13 2007-04-19 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 관련 장애를 위한 가바펜틴 유사체
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
KR20050119676A (ko) * 2003-03-31 2005-12-21 제노포트 인코포레이티드 가바 유사체의 프로드러그를 사용한 열성 홍조의 치료 또는예방
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
BRPI0413756A (pt) * 2003-08-20 2006-10-31 Xenoport Inc composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
JP2007505095A (ja) * 2003-09-12 2007-03-08 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ
NZ579515A (en) * 2003-09-17 2011-09-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
EP1670750A1 (en) * 2003-09-25 2006-06-21 Warner-Lambert Company LLC Prodrugs of amino acids with affinity for the alpha2delta- protein
SG147437A1 (en) * 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
MX2007005306A (es) * 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
US20060192353A1 (en) * 2005-02-08 2006-08-31 Schubert Peter J Method of producing a rollover arming signal based on off-axis acceleration
WO2007027477A2 (en) * 2005-08-23 2007-03-08 Xenoport, Inc. Treating vulvodynia using prodrugs of gaba analogs
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
EA200970483A1 (ru) * 2006-11-14 2009-12-30 Ксенопорт, Инк. Применение пролекарств габапентина и прегабалина для лечения шума в ушах
EP2250148B1 (en) * 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US7868043B2 (en) * 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use

Also Published As

Publication number Publication date
WO2008073257A1 (en) 2008-06-19
EP2101752A1 (en) 2009-09-23
AU2007332904A1 (en) 2008-06-19
CA2672044A1 (en) 2008-06-19
TW200845959A (en) 2008-12-01
US20080161393A1 (en) 2008-07-03
JP2010512314A (ja) 2010-04-22
PE20081389A1 (es) 2008-11-19
BRPI0720252A2 (pt) 2014-01-07
EA200970487A1 (ru) 2009-12-30
AR064212A1 (es) 2009-03-18
CN101652133A (zh) 2010-02-17
US20120041061A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
MX2009006080A (es) Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
MX2010004614A (es) Composiciones para tratamiento del mal de parkinson.
WO2010022177A3 (en) Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2011106573A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EP2214712A4 (en) COMPOSITIONS AND METHODS OF TREATING ASTHMA AND LUNG DISEASES
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
EP2341943A4 (en) COMPOSITIONS AND METHODS FOR SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA OWING MODIFICATIONS
MX355742B (es) Análogos deuterados del ácido 4-hidroxibutírico.
UA98373C2 (ru) Конденсированные гетероциклические производные и их применение как c-met ингибиторов
PH12012500620A1 (en) Compounds
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
MX2009004289A (es) Compuestos triciclicos como inhibidores de metaloproteinasas matriciales.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
PH12015500301B1 (en) A novel formulation of diclofenac
MY162499A (en) Methylphenidate-prodrugs, processes of making and using the same
EA200970883A1 (ru) Индолкарбоксамиды как ингибиторы ikk2
EP2016187A4 (en) COMPOSITIONS AND METHOD FOR THE ENZYMATIC TREATMENT OF LUNG DISEASES
WO2009158432A3 (en) Ang-2 inhibition to treat multiple sclerosis
MX2009002740A (es) Inhibidores de renina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal